PROGNOSTIC SIGNIFICANCE OF SST2 IN HEART FAILURE WITH REDUCED EJECTION FRACTION, A BIOMARKER OF CARDIOVASCULAR MORTALITY AND REHOSPITALIZATION.

Introduction: Heart failure (HF) poses a substantial burden on healthcare systems and society, necessitating effective diagnostic tools for enhanced patient management. The soluble suppression of tumorigenesis 2 protein (Soluble Suppression of Tumorigenesis 2 (sST2)) has emerged as a promising biomarker linked to cardiac remodeling and fibrosis. This study investigates Soluble Suppression of Tumorigenesis 2 (sST2)'s potential as a diagnostic and prognostic marker for chronic heart failure (CHF) and explores its clinical utility in predicting outcomes.